FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to N-(2-thiazolyl)amide derivatives of formula 
wherein R1 and R2 are independently selected from H, -NO2, fluorine, chlorine and iodine, provided at least one of R1 and R2 is different from H; m is equal to 1 or 2, or to its pharmaceutically acceptable salts.
EFFECT: invention refers to a method for preparing said compounds, based pharmaceutical composition and applying them for preparing a drug for treating or preventing GSK-3 mediated diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's disease or insulin-independent diabetes.
24 cl, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2429237C2 |
| GSK-3 INHIBITORS | 2006 |
|
RU2449998C2 |
| GSK-3 INHIBITORS | 2005 |
|
RU2379300C2 |
| SELECTIVE BUTYRYLCHOLIN ESTERASE INHIBITORS | 2005 |
|
RU2386627C2 |
| HETEROCYCLIC INHIBITORS OF GLYCOGEN SYNTHASE-KINASE GSK-3 | 2001 |
|
RU2294931C2 |
| TACRINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS | 2004 |
|
RU2402545C2 |
| IMIDAZOLE DERIVATIVES ACTIVE TO CB1 RECEPTOR | 2005 |
|
RU2377238C2 |
| TRIAZOLES USED AS PROTEIN KINASE INHIBITORS | 2005 |
|
RU2393155C2 |
| SYNTHESIS AND USE OF TETRAHYDROPYROLLO[3,2-c]PYRIDIN-4-ONE DERIVATIVES TO TREAT OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | 2006 |
|
RU2415856C2 |
| METABOLITES OF ALPHA-HYDROXYLATED FATTY ACIDS, MEDICAL APPLICATIONS AND USE THEREOF AS BIOMARKERS | 2021 |
|
RU2841595C1 |
